BR112016017996A2 - 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso - Google Patents
6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de usoInfo
- Publication number
- BR112016017996A2 BR112016017996A2 BR112016017996A BR112016017996A BR112016017996A2 BR 112016017996 A2 BR112016017996 A2 BR 112016017996A2 BR 112016017996 A BR112016017996 A BR 112016017996A BR 112016017996 A BR112016017996 A BR 112016017996A BR 112016017996 A2 BR112016017996 A2 BR 112016017996A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- carboxamides
- heteroaryloxy
- quinoline
- aryloxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 abstract 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 abstract 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 abstract 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 abstract 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936397P | 2014-02-06 | 2014-02-06 | |
| PCT/US2015/014380 WO2015119998A1 (en) | 2014-02-06 | 2015-02-04 | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016017996A2 true BR112016017996A2 (pt) | 2017-08-08 |
Family
ID=52484589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016017996A BR112016017996A2 (pt) | 2014-02-06 | 2015-02-04 | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9452986B2 (enExample) |
| EP (1) | EP3102569A1 (enExample) |
| JP (1) | JP6532474B2 (enExample) |
| KR (1) | KR20160118345A (enExample) |
| CN (1) | CN106458985B (enExample) |
| AU (1) | AU2015214366B2 (enExample) |
| BR (1) | BR112016017996A2 (enExample) |
| CA (1) | CA2938719A1 (enExample) |
| HK (1) | HK1231471A1 (enExample) |
| IL (1) | IL247014A0 (enExample) |
| MX (1) | MX2016010056A (enExample) |
| RU (1) | RU2016135637A (enExample) |
| SG (1) | SG11201606367YA (enExample) |
| WO (1) | WO2015119998A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| IL311677B2 (en) | 2014-01-13 | 2025-06-01 | Aurigene Oncology Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| KR20160118345A (ko) * | 2014-02-06 | 2016-10-11 | 애브비 인코포레이티드 | 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도 |
| US20170152263A1 (en) * | 2014-06-20 | 2017-06-01 | Aurigene Discovery Technologies Limited | Substituted Indazole Compounds as IRAK4 Inhibitors |
| US9611262B2 (en) * | 2014-09-11 | 2017-04-04 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
| US10441586B2 (en) | 2015-10-07 | 2019-10-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | CRMP2 SUMOylation inhibitors and uses thereof |
| SI3359541T1 (sl) * | 2015-10-09 | 2021-01-29 | Abbvie Overseas S.A R.L. | N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe |
| CN110337436A (zh) | 2016-12-22 | 2019-10-15 | 拜耳作物科学股份公司 | 取代的1,2,4-噻二唑基吡咯酮和1,2,4-噻二唑基乙内酰脲及其盐及其作为除草剂的用途 |
| WO2018178947A2 (en) | 2017-03-31 | 2018-10-04 | Aurigene Discovery Technologies Limited | Compounds and compositions for treating hematological disorders |
| AU2018293627B2 (en) * | 2017-06-30 | 2022-07-21 | Elanco Animal Health Gmbh | New azaquinoline derivatives |
| MY203827A (en) | 2017-10-31 | 2024-07-19 | Curis Inc | Compounds and compositions for treating hematological disorders |
| KR102840599B1 (ko) | 2018-07-09 | 2025-07-29 | 리버 인스티튜트, 아이엔씨 | Nav1.8을 억제하기 위한 피리다진(PYRIDAZINE) 화합물 |
| SG11202100130QA (en) | 2018-07-09 | 2021-02-25 | Lieber Institute Inc | Pyridine carboxamide compounds for inhibiting nav1.8 |
| HRP20241195T1 (hr) | 2018-09-10 | 2024-11-22 | Kaken Pharmaceutical Co., Ltd. | Novi heteroaromatski amidni derivat i lijek koji ga sadrži |
| AU2019375983A1 (en) | 2018-11-09 | 2021-06-10 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| CN113784713A (zh) * | 2019-01-11 | 2021-12-10 | 纳吉斯制药股份有限公司 | 白三烯合成抑制剂 |
| EP3956033B1 (en) * | 2019-04-16 | 2024-12-11 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| AU2022254933A1 (en) | 2021-04-08 | 2023-11-09 | Curis, Inc. | Combination therapies for the treatment of cancer |
| US20250115578A1 (en) * | 2022-01-18 | 2025-04-10 | Chengdu Kanghong Pharmaceutical Co., Ltd. | Aromatic fused ring nav1.8 inhibitor, and use thereof |
| TW202434557A (zh) | 2022-11-09 | 2024-09-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| WO2025078263A1 (en) | 2023-10-11 | 2025-04-17 | Syngenta Crop Protection Ag | Microbiocidal pyridyl pyrazole derivatives |
| WO2025233384A1 (en) | 2024-05-08 | 2025-11-13 | Syngenta Crop Protection Ag | Microbiocidal pyrazole compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1663994B1 (en) * | 2003-08-05 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels |
| KR100867071B1 (ko) * | 2004-10-19 | 2008-11-04 | 에프. 호프만-라 로슈 아게 | 퀴놀린 유도체 |
| CN101218226A (zh) * | 2005-05-16 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
| GB0513692D0 (en) * | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| MX2008002731A (es) * | 2005-09-01 | 2008-03-26 | Hoffmann La Roche | Diaminopirimidinas como moduladores de p2x3 y p3x2/3. |
| KR101402474B1 (ko) | 2006-04-26 | 2014-06-19 | 제넨테크, 인크. | 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물 |
| MX2009003876A (es) * | 2006-10-12 | 2009-05-11 | Xenon Pharmaceuticals Inc | Uso de compuestos de espiro-oxindol como agentes terapeuticos. |
| SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| CN102448937A (zh) * | 2009-05-29 | 2012-05-09 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| WO2011058766A1 (en) * | 2009-11-16 | 2011-05-19 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as ttx-s blockers |
| US8394829B2 (en) * | 2010-05-10 | 2013-03-12 | Gilead Sciences, Inc. | Bi-functional quinoline analogs |
| RU2535671C1 (ru) * | 2010-10-18 | 2014-12-20 | Раквалиа Фарма Инк. | Производные ариламидов в качестве блокаторов ttx-s |
| AR095192A1 (es) * | 2013-01-31 | 2015-09-30 | Vertex Pharma | Quinolina y quinazolinamidas como modulares de canales de sodio |
| KR20160118345A (ko) * | 2014-02-06 | 2016-10-11 | 애브비 인코포레이티드 | 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도 |
-
2015
- 2015-02-04 KR KR1020167024669A patent/KR20160118345A/ko not_active Withdrawn
- 2015-02-04 SG SG11201606367YA patent/SG11201606367YA/en unknown
- 2015-02-04 MX MX2016010056A patent/MX2016010056A/es unknown
- 2015-02-04 WO PCT/US2015/014380 patent/WO2015119998A1/en not_active Ceased
- 2015-02-04 RU RU2016135637A patent/RU2016135637A/ru not_active Application Discontinuation
- 2015-02-04 CA CA2938719A patent/CA2938719A1/en not_active Abandoned
- 2015-02-04 AU AU2015214366A patent/AU2015214366B2/en not_active Ceased
- 2015-02-04 US US14/613,579 patent/US9452986B2/en active Active
- 2015-02-04 HK HK17105028.6A patent/HK1231471A1/zh unknown
- 2015-02-04 JP JP2016550611A patent/JP6532474B2/ja not_active Expired - Fee Related
- 2015-02-04 CN CN201580017702.3A patent/CN106458985B/zh not_active Expired - Fee Related
- 2015-02-04 BR BR112016017996A patent/BR112016017996A2/pt not_active Application Discontinuation
- 2015-02-04 EP EP15705447.9A patent/EP3102569A1/en not_active Withdrawn
-
2016
- 2016-07-28 IL IL247014A patent/IL247014A0/en unknown
- 2016-08-17 US US15/239,554 patent/US9969693B2/en active Active
-
2018
- 2018-04-13 US US15/952,682 patent/US20180334435A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN106458985A (zh) | 2017-02-22 |
| MX2016010056A (es) | 2016-11-15 |
| US20180334435A1 (en) | 2018-11-22 |
| US9452986B2 (en) | 2016-09-27 |
| US20150218102A1 (en) | 2015-08-06 |
| IL247014A0 (en) | 2016-09-29 |
| JP6532474B2 (ja) | 2019-06-19 |
| RU2016135637A (ru) | 2018-03-12 |
| CN106458985B (zh) | 2019-05-03 |
| KR20160118345A (ko) | 2016-10-11 |
| AU2015214366A1 (en) | 2016-08-18 |
| WO2015119998A1 (en) | 2015-08-13 |
| US9969693B2 (en) | 2018-05-15 |
| US20160355482A1 (en) | 2016-12-08 |
| AU2015214366B2 (en) | 2019-04-18 |
| HK1231471A1 (zh) | 2017-12-22 |
| EP3102569A1 (en) | 2016-12-14 |
| CA2938719A1 (en) | 2015-08-13 |
| US20170226062A9 (en) | 2017-08-10 |
| RU2016135637A3 (enExample) | 2018-08-27 |
| SG11201606367YA (en) | 2016-09-29 |
| JP2017505327A (ja) | 2017-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016017996A2 (pt) | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| BR112017009194A2 (pt) | tetra-hidropiranos substituídos e método de uso | |
| CO2017012566A2 (es) | Piridinas sustituidas y método de uso | |
| BR112017002811A2 (pt) | compostos de pirrolopirimidina usados como agonista de tlr7 | |
| BR112017027831A2 (pt) | derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| BR112018075433A2 (pt) | derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
| CL2015002855A1 (es) | Derivados de oxopiridina sustituida. | |
| MX382991B (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
| BR112015020350A2 (pt) | derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| ECSP16074478A (es) | Compuestos novedosos | |
| ECSP17069696A (es) | Compuestos novedosos | |
| EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
| BR112016018418A2 (pt) | Composto, uso do mesmo, e composição farmacêutica | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| MX377032B (es) | Compuestos de dihidroquinolinsulfonamida de alquilo. | |
| BR112015022207A2 (pt) | forma cristalina do composto i, formas cristalinas de sais do composto i e método para o tratamento de melanoma | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| EA201600394A1 (ru) | Трициклические соединения пиперидина | |
| MX2015013151A (es) | Métodos de tratamiento de disquinesia y trastornos relacionados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |